This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cheung, N.-K. V. Articles by Cheung, I. Y. Search for Related Content PubMed PubMed Citation Articles by Cheung, N.-K. V. Articles by Cheung, I. Y.

Induction of Ab3 and Ab3' Antibody Was Associated with Long-Term Survival after Anti-G_D2 Antibody Therapy of Stage 4 Neuroblastoma¹

Departments of Pediatrics [N-K. V. C., H-f. G., I. Y. C.] and Biostatistics [G. H.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Treatment with anti-G_D2 monoclonal antibody 3F8 (Ab1) at the time of remission may prolong survival for children with stage 4 neuroblastoma. A transient human antimouse antibody (HAMA) response was associated with significantly longer survival (Cheung et al., J. Clin. Oncol., 16: 3053–3060, 1998). Because this response was primarily anti-idiotypic (Ab2), we postulate that the subsequent induction of an idiotype network that included an elevation of anti-anti-idiotypic (Ab3) and anti-G_D2 (Ab3') antibody titers may be responsible for tumor control. Thirty-four patients with stage 4 neuroblastoma diagnosed at >1 year of age were treated with 3F8 at the end of chemotherapy. Most had either bone marrow (31 of 34) or distant bony (29 of 34) metastases at diagnosis. Thirteen patients were treated at second or subsequent remission, and 12 patients in this group had a history of progressive/persistent disease after bone marrow transplantation; 21 patients were treated in the first remission after N6 chemotherapy. Their serum HAMA, Ab3, and Ab3' titers prior to, at 6, and at 14 months after antibody treatment were measured by ELISA. Among these 34 patients, 14 are alive, and 13 (1.8–7.4 years at diagnosis) are progression free (53–143 months from the initiation of 3F8 treatment) without further systemic therapy. Long-term progression-free survival (PFS) and survival correlated significantly with Ab3' (anti-G_D2) response at 6 months and with Ab3 response at 6 and 14 months. By defining Ab3 threshold ranging from the ratio of 1.1 to 2.6 above pretreatment level, the difference in PFS and survival between the high-Ab3 and low-Ab3 groups became markedly widened. Similarly, increasing the Ab3' threshold at either 6 or 14 months to 300% above pre-3F8 levels also increased the spread between the high versus low Ab3' groups for both PFS and survival curves. Non-idiotype antibody responses (anti-mouse-IgG3 or anti-tumor nuclear HUD antigen) had no apparent impact on PFS or survival. In conclusion, despite the high-risk nature of stage 4 neuroblastoma, long-term remission without myeloablative therapy can be achieved with 3F8 treatment. Ab3 and Ab3' antibody response correlated with prolonged PFS and survival. We postulate that successful induction of an idiotype network in patients may be responsible for long-term tumor control.

This article has been cited by other articles:

				N. Alvarez-Rueda, S. Leprieur, B. Clemenceau, S. Supiot, V. Sebille-Rivain, A. Faivre-Chauvet, F. Davodeau, F. Paris, J. Barbet, J. Aubry, et al. Binding Activities and Antitumor Properties of a New Mouse/Human Chimeric Antibody Specific for GD2 Ganglioside Antigen Clin. Cancer Res., September 15, 2007; 13(18): 5613s - 5620s. [Abstract] [Full Text] [PDF]

				M. M. Uttenreuther-Fischer, J. A. Kruger, and P. Fischer Molecular Characterization of the Anti-Idiotypic Immune Response of a Relapse-Free Neuroblastoma Patient following Antibody Therapy: A Possible Vaccine against Tumors of Neuroectodermal Origin? J. Immunol., June 15, 2006; 176(12): 7775 - 7786. [Abstract] [Full Text] [PDF]

				E. Bolesta, A. Kowalczyk, A. Wierzbicki, P. Rotkiewicz, B. Bambach, C.-Y. Tsao, I. Horwacik, A. Kolinski, H. Rokita, M. Brecher, et al. DNA Vaccine Expressing the Mimotope of GD2 Ganglioside Induces Protective GD2 Cross-reactive Antibody Responses Cancer Res., April 15, 2005; 65(8): 3410 - 3418. [Abstract] [Full Text] [PDF]

				M. Z. Lin, M. A. Teitell, and G. J. Schiller The Evolution of Antibodies into Versatile Tumor-Targeting Agents Clin. Cancer Res., January 1, 2005; 11(1): 129 - 138. [Abstract] [Full Text] [PDF]

				T. Simon, B. Hero, A. Faldum, R. Handgretinger, M. Schrappe, D. Niethammer, and F. Berthold Consolidation Treatment With Chimeric Anti-GD2-Antibody ch14.18 in Children Older Than 1 Year With Metastatic Neuroblastoma J. Clin. Oncol., September 1, 2004; 22(17): 3549 - 3557. [Abstract] [Full Text] [PDF]

				B. M. Bradt, S. J. DeNardo, G. R. Mirick, and G. L. DeNardo Documentation of Idiotypic Cascade after Lym-1 Radioimmunotherapy in a Patient with Non-Hodgkin's Lymphoma: Basis for Extended Survival? Clin. Cancer Res., September 1, 2003; 9(10): 4007S - 4012. [Abstract] [Full Text] [PDF]

				K. A. Foon and M. Bhattacharya-Chatterjee Are Solid Tumor Anti-Idiotype Vaccines Ready for Prime Time?: Commentary re: U. Wagner et al., Immunological Consolidation of Ovarian Carcinoma Recurrences with Monoclonal Anti-Idiotype Antibody ACA125: Immune Responses and Survival in Palliative Treatment. Clin. Cancer Res., 7: 1154-1162, 2001. Clin. Cancer Res., May 1, 2001; 7(5): 1112 - 1115. [Full Text]